NLRP3 and metabolic dysfunction-associated steatohepatitis: The researchers also identified MCC950 as a highly effective and selective NLRP3 inhibitor, demonstrating the ability to mitigate hepatic injury and fibrotic progression of NASH by inhibiting NLRP3 activation (Mridha et al., 2017b).